Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215520) titled 'Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults' on Oct. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: CastleVax Inc.
Condition:
COVID-19
Intervention:
Biological: NDV-HXP-S-KP.2
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 20, 2025
Target Sample Size: 200
Countries of Recruitment:
United States
To know more,...